Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCalleja-Agius, Jean-
dc.contributor.authorBrincat, Mark-
dc.identifier.citationCalleja-Agius, J., & Brincat, M. (2013). Is clomifene citrate the best first-line treatment for anovulation? Gynecology Forum, 18(4), 20-23.en_GB
dc.description.abstractIn 1961, Greenblatt et al. were the first to report on the potential use of a novel compound, MRL-41, later known as clomifene citrate, to induce ovulation in anovulatory women. This was a very welcome breakthrough, because until then the only effective treatment available to help anovulatory women conceive was bilateral wedge resection of the ovaries, with the risk of consequent severe abdominal adhesions. Clomifene citrate has since been widely used as firstline treatment for women with hypothalamic–pituitary– ovarian axis dysfunction causing euestrogenic oligo- or anovulation (WHO group II), 80% of whom suffer from polycystic ovary syndrome (PCOS). Clomifene citrate remains an effective medication in treating this group of infertile women and achieves a single live birth rate of approximately 25%. It is acceptable to women, since it is administered orally, and is relatively cheap. Recently, clomifene citrate has also been used in controlled ovarian stimulation in patients with unexplained infertility. Although in this case the results are less exciting, clomifene citrate is being used as a substitute for the more expensive gonadotropin injections for superovulation accompanying intrauterine insemination or in vitro fertilization. For example, the sequential clomifene citrate/human menopausal gonadotropin (hMG) regimen is as effective as hMG alone, with satisfactory pregnancy rates but much reduced costs.en_GB
dc.publisherMedical Forum Internationalen_GB
dc.subjectOvaries -- Diseasesen_GB
dc.subjectPremature ovarian failureen_GB
dc.subjectInfertility, Femaleen_GB
dc.titleIs clomifene citrate the best first-line treatment for anovulation?en_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.publication.titleGynecology Forumen_GB
Appears in Collections:Scholarly Works - FacM&SAna

Files in This Item:
File Description SizeFormat 
  Restricted Access
105.47 kBAdobe PDFView/Open Request a copy

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.